Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Olaparib in Ovarian Cancer: NCT07453394 Clinical Landscape Report 2026
18 September 2026
NCT07453394 clinical landscape for Ovarian Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab/Relatlimab in Metastatic melanoma: NCT07459543 Clinical Landscape Report 2026
18 September 2026
NCT07459543 clinical landscape for Metastatic melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BCMA-Targeted CAR T-Cell(Chulalongkorn University) in Multiple Myeloma: NCT07458659 Clinical Landscape Report 2026
18 September 2026
NCT07458659 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
177Lu-INN805 in Sarcoma: NCT07459283 Clinical Landscape Report 2026
18 September 2026
NCT07459283 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Doxorubicin Hydrochloride in Metastatic Soft Tissue Sarcoma: NCT07460986 Clinical Landscape Report 2026
18 September 2026
NCT07460986 clinical landscape for Metastatic Soft Tissue Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
TCR-T cells targeting MAGE-A4(Sun Yat-Sen Memorial Hospital) in Sarcoma: NCT07467122 Clinical Landscape Report 2026
18 September 2026
NCT07467122 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HWK-016 in Endometrial Carcinoma: NCT07470853 Clinical Landscape Report 2026
18 September 2026
NCT07470853 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GLP-1 agonist (Nxera Pharma) in Endometrioid intraepithelial neoplasia: NCT07462663 Clinical Landscape Report 2026
18 September 2026
NCT07462663 clinical landscape for Endometrioid intraepithelial neoplasia: endpoints, sponsor, phase, geography, readouts, asset context and development whit…
9 min read
Fludeoxyglucose F-18 in Recurrent Multiple Myeloma: NCT07463807 Clinical Landscape Report 2026
18 September 2026
NCT07463807 clinical landscape for Recurrent Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
SM-17 in Asthma: NCT07466940 Clinical Landscape Report 2026
18 September 2026
NCT07466940 clinical landscape for Asthma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HS-10566 in Non-Muscle Invasive Bladder Neoplasms: NCT07468851 Clinical Landscape Report 2026
18 September 2026
NCT07468851 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Pembrolizumab biosimilar(Alvotech) in Melanoma: NCT07475572 Clinical Landscape Report 2026
18 September 2026
NCT07475572 clinical landscape for Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.